Latest News
-
1:10 Stock Split: 1 Rs 980 Smallcap Has Split Into Ten Shares; Check Out New Price Level, Fundamentals! -
Rs 2.50/Share Final Dividend: Record Date In Due Course; Buy The ITC Group Stock? -
Rs 95/Share Dividend: Record Date On 28th June; Buy Mahindra Group Stock To Be Eligible? -
5 Bonus, Rs 28/Sh Dividend: IT Giant Infosys Beats Estimates In Q4FY24, But ADR Falls Sharply; Here's Why! -
1:10 Stock Split Approved: Small Cap Stock Issues Warrants, Shares Gain 111% YTD -
Wipro Q4 Results Preview: Weak Demand Likely To Drag Revenue Sequentially, EBIT Margins Seen Stable -
Rs 6/Share Final Dividend Declared: Buy The Blue Chip Stock To Be Eligible? -
TCS Vs Infosys: Dividend History And Upcoming Rewards, Which IT Giant Is Better? -
LIC New Jeevan Shanti 858 Plan: How To Earn Rs 10,000 Pension Per Month After Retirement? Check Eligibility! -
Kronox Lab Sciences Granted SEBI Approval to Initiate IPO
For Daily Alerts
Ranbaxy Q4 loss at whopping Rs 2,893 crores
The company posted whopping loss of Rs 2,983 crore for the quarter ended December 31, 2012.
Foreign exchange losses which were pegged at Rs 1,080 crore, further aggravated the company's losses. Sales jumped 79% during the Q4 from Rs 2,091 to Rs 3,741, on the back of "Lipitor" sales in the US.
The shares of the company on BSE were trading lower at Rs 435.80, down Rs 4.50 at 10: 50 am IST.
Ranbaxy Laboratories is India's largest pharmaceutical company, with a presence in 23 of the top 25 pharmaceutical markets of the world.
GoodRetruns.in
Story first published: Friday, February 24, 2012, 11:03 [IST]
More From GoodReturns
